Differential Angiogenic Gene Expression in TP53 Wild-Type and Mutant Ovarian Cancer Cell Lines
Brittany A. Davidson(Duke Medical Center), Angeles Alvarez Secord(Duke University), Kouros Owzar(Duke University), Andrew Berchuck(General Marble (Greece)), William John Soper(Duke University), David L. Corcoran(NHS Greater Glasgow and Clyde), Jennifer M. Rubatt(Duke University), L. Grace(Duke University), Susan K. Murphy(Duke University), Wei Chen(Duke University), Sharareh Siamakpour‐Reihani(Duke University), Deanna Teoh(Duke University), Marcus Q. Bernardini(University Health Network)
Cited by 40
Related Papers
Integrated genomic analyses of ovarian carcinoma
|Nature|2011|8.2k
Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial
|The Lancet|2009|1.4k
Lenalidomide after Stem-Cell Transplantation for Multiple Myeloma
|New England Journal of Medicine|2012|1.2k
Correlation of Kinase Genotype and Clinical Outcome in the North American Intergroup Phase III Trial of Imatinib Mesylate for Treatment of Advanced Gastrointestinal Stromal Tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology Group
|Journal of Clinical Oncology|2008|655
Genomic and epigenetic evidence for oxytocin receptor deficiency in autism
|BMC Medicine|2009|580